ABSTRACT
Metal organic frameworks (MOFs) that incorporate metal oxide cluster nodes, exemplified by UiO-66, have been widely studied, especially in terms of their deviations from the ideal, defect-free crystalline structures. Although defects such as missing linkers, missing nodes, and the presence of adventitious synthesis-derived node ligands (such as acetates and formates) have been proposed, their exact structures remain unknown. Previously, it was demonstrated that defects are correlated and span multiple unit cells. The highly specialized techniques used in these studies are not easily applicable to other MOFs. Thus, there is a need to develop new experimental and computational approaches to understand the structure and properties of defects in a wider variety of MOFs. Here, we show how low-frequency phonon modes measured by inelastic neutron scattering (INS) spectroscopy can be combined with density functional theory (DFT) simulations to provide unprecedented insights into the defect structure of UiO-66. We are able to identify and assign peaks in the fingerprint region (<100 cm-1) which correspond to phonon modes only present in certain defective topologies. Specifically, this analysis suggests that our sample of UiO-66 consists of predominantly defect-free fcu regions with smaller domains corresponding to a defective bcu topology with 4 and 2 acetate ligands bound to the Zr6O8 nodes. Importantly, the INS/DFT approach provides detailed structural insights (e.g., relative positions and numbers of acetate ligands) that are not accessible with microscopy-based techniques. The quantitative agreement between DFT simulations and the experimental INS spectrum combined with the relative simplicity of sample preparation, suggests that this methodology may become part of the standard and preferred protocol for the characterization of MOFs, and, in particular, for elucidating the structure defects in these materials.
ABSTRACT
Knowledge of the full phonon spectrum is essential to accurately calculate the dynamic disorder (σ) and hole mobility (µh) in organic semiconductors (OSCs). However, most vibrational spectroscopy techniques under-measure the phonons, thus limiting the phonon validation. Here, we measure and model the full phonon spectrum using multiple spectroscopic techniques and predict µh using σ from only the Γ-point and the full Brillouin zone (FBZ). We find that only inelastic neutron scattering (INS) provides validation of all phonon modes, and that σ in a set of small molecule semiconductors can be miscalculated by up to 28% when comparing Γ-point against FBZ calculations. A subsequent mode analysis shows that many modes contribute to σ and that no single mode dominates. Our results demonstrate the importance of a thoroughly validated phonon calculation, and a need to develop design rules considering the full spectrum of phonon modes.
ABSTRACT
Atomic vibrations can inform about materials properties from hole transport in organic semiconductors to correlated disorder in metal-organic frameworks. Currently, there are several methods for predicting these vibrations using simulations, but the accuracy-efficiency tradeoffs have not been examined in depth. In this study, rubrene is used as a model system to predict atomic vibrational properties using six different simulation methods: density functional theory, density functional tight binding, density functional tight binding with a Chebyshev polynomial-based correction, a trained machine learning model, a pretrained machine learning model called ANI-1, and a classical forcefield model. The accuracy of each method is evaluated by comparison to the experimental inelastic neutron scattering spectrum. All methods discussed here show some accuracy across a wide energy region, though the Chebyshev-corrected tight-binding method showed the optimal combination of high accuracy with low expense. We then offer broad simulation guidelines to yield efficient, accurate results for inelastic neutron scattering spectrum prediction.
ABSTRACT
BACKGROUND: Brain structure abnormalities throughout the course of Parkinson's disease have yet to be fully elucidated. OBJECTIVE: Using a multicenter approach and harmonized analysis methods, we aimed to shed light on Parkinson's disease stage-specific profiles of pathology, as suggested by in vivo neuroimaging. METHODS: Individual brain MRI and clinical data from 2357 Parkinson's disease patients and 1182 healthy controls were collected from 19 sources. We analyzed regional cortical thickness, cortical surface area, and subcortical volume using mixed-effects models. Patients grouped according to Hoehn and Yahr stage were compared with age- and sex-matched controls. Within the patient sample, we investigated associations with Montreal Cognitive Assessment score. RESULTS: Overall, patients showed a thinner cortex in 38 of 68 regions compared with controls (dmax = -0.20, dmin = -0.09). The bilateral putamen (dleft = -0.14, dright = -0.14) and left amygdala (d = -0.13) were smaller in patients, whereas the left thalamus was larger (d = 0.13). Analysis of staging demonstrated an initial presentation of thinner occipital, parietal, and temporal cortices, extending toward rostrally located cortical regions with increased disease severity. From stage 2 and onward, the bilateral putamen and amygdala were consistently smaller with larger differences denoting each increment. Poorer cognition was associated with widespread cortical thinning and lower volumes of core limbic structures. CONCLUSIONS: Our findings offer robust and novel imaging signatures that are generally incremental across but in certain regions specific to disease stages. Our findings highlight the importance of adequately powered multicenter collaborations. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Subject(s)
Parkinson Disease , Brain/diagnostic imaging , Brain/pathology , Humans , Magnetic Resonance Imaging , Neuroimaging , Parkinson Disease/complications , Thalamus/pathologyABSTRACT
BACKGROUND: While studies have shown the progression of atrophy in temporal lobe epilepsy (TLE) with hippocampal sclerosis (HS), little is known about the long-term dynamics of interictal epileptiform discharges (IEDs). OBJECTIVES: To investigate long-term IEDs distribution in routine EEGs. METHODS: We evaluated 314 patients with TLE and MRI signs of HS (TLE-HS). Six had bilateral, 163 had left, and 145 had right HS. We analyzed 3655 routine EEGs (average 11.6 EEGs/patient). The EEGs were classified into four groups: (i) ipsilateral-IEDs (n = 1485), EEGs with only IEDs ipsilateral to the HS; (ii) bilateral-IEDs (n = 390); (iii) contralateral-IEDs (n = 186); and (iv) normal-EEGs (n = 1594). The duration of epilepsy at the time of the EEG (average 27.9 years) was divided into four groups: (a) <8 years (n = 140), (b) 9-17 years (n = 505), (c) 18-29 years (n = 1165), and (d) >30 years (n = 1845). We performed ANOVA with Tukey's pairwise comparisons and linear regression analysis between the duration of epilepsy and the EEG groups. RESULTS: The ANOVA showed a difference in the distribution of IEDs over time (p < 0.0001). While there were no significant changes in the relative numbers of bilateral and contralateral-IEDs combined, there was a significant increase in ipsilateral-IEDs (p < 0.0001) and a decrease in normal-EEGs (p < 0.0001) over time. The linear regression analysis confirmed that the proportion of ipsilateral-IEDs (p < 0.0001), and to a lesser extent, bilateral-IEDs (p = 0.0002), increased over time, while contralateral-IEDs were unchanged (p = 0.923). CONCLUSIONS: Contrary to our expectations, contralateral-IEDs remained stable over time, whereas normal-EEGs decreased and ipsilateral-IEDs increased. Contralateral-IEDs may reflect early abnormalities and not epilepsy progression.
Subject(s)
Epilepsy, Temporal Lobe , Epilepsy , Electroencephalography , Epilepsy/pathology , Epilepsy, Temporal Lobe/diagnostic imaging , Epilepsy, Temporal Lobe/pathology , Hippocampus/diagnostic imaging , Hippocampus/pathology , Humans , Magnetic Resonance Imaging , Sclerosis/pathologyABSTRACT
A lipid nanoemulsion (LDE) resembling low-density lipoprotein can target malignant tumours. In in vivo and clinical studies, association of chemotherapeutic agents to LDE decreased their toxicity and increased pharmacological action. Here, safety of LDE as carmustine carrier (50 mg m(-2) , intravenous) combined with vincristine and prednisone for the treatment of dogs with lymphoma was tested and compared with commercial carmustine with vincristine and prednisone. In five dogs from LDE-carmustine and six from commercial carmustine, complete remission was achieved (P > 0.05). Partial remission occurred in two dogs from each group. In both groups, the median progression-free intervals (119 and 199 days) and overall survival times (207 and 247 days) were equal. Neutropenia was observed in both groups, but no other major toxicities occurred. Therefore, no difference was observed between the treatments. LDE-carmustine was shown to be safe and effective in a drug combination protocol, which encourages larger studies to investigate the use of this novel formulation to treat canine lymphomas.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carmustine/administration & dosage , Dog Diseases/drug therapy , Lymphoma, B-Cell/veterinary , Lymphoma, T-Cell/veterinary , Animals , Antineoplastic Agents, Alkylating/administration & dosage , Antineoplastic Agents, Alkylating/adverse effects , Antineoplastic Agents, Hormonal/administration & dosage , Antineoplastic Agents, Hormonal/adverse effects , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Brazil , Carmustine/adverse effects , Disease-Free Survival , Dog Diseases/diagnosis , Dogs , Fat Emulsions, Intravenous/administration & dosage , Female , Kaplan-Meier Estimate , Lymphoma, B-Cell/diagnosis , Lymphoma, B-Cell/drug therapy , Lymphoma, T-Cell/diagnosis , Lymphoma, T-Cell/drug therapy , Male , Pilot Projects , Prednisone/administration & dosage , Prednisone/adverse effects , Vincristine/administration & dosage , Vincristine/adverse effectsABSTRACT
AIM: Infective agents may affect pregnancy outcomes by deregulating homeostasis. OBJECTIVES: The effects of Porphyromonas gingivalis infection before and at different gestation periods were evaluated. MATERIALS AND METHODS: Wistar rats infected via subcutaneous with P. gingivalis W83, one week before mating (BM), days 1 (PR1) and 11 of gestation (PR11), and controls were evaluated, and samples were obtained at the end of gestation. P. gingivalis was detected by PCR. Cytokine was determined by ELISA. RESULTS: Infected rats had lower maternal gain of weight. Implantation was not observed in 2/12 BM rats. PR11 presented more fetal-placental resorptions and lower placenta/fetus weight than controls. P. gingivalis was detected in placenta and fetus. IL-6 and TNF-α levels were higher in placenta and serum of infected groups, except for TNF-α in placenta of PR1. IL-1ß levels were higher in placenta of PR11, but lower in serum and placenta of PR1. There were no differences in IL-10 and PGE2 concentrations among the groups (P < 0.05). CONCLUSIONS: The experimental infection by P. gingivalis resulted in alterations in the gestational pattern and in fetal development. The consequences of infection at mid-gestation were more severe than at the beginning, possibly due to the induction of pro-inflammatory cytokines in the fetal compartment.
Subject(s)
Bacteroidaceae Infections , Fetal Development , Porphyromonas gingivalis , Pregnancy Complications, Infectious , Animals , Bacteroidaceae Infections/blood , DNA, Bacterial/analysis , Dinoprostone/analysis , Dinoprostone/blood , Female , Gestational Age , Interleukin-1beta/analysis , Interleukin-1beta/blood , Interleukin-6/analysis , Interleukin-6/blood , Maternal-Fetal Exchange , Placenta/chemistry , Placenta/microbiology , Pregnancy , Pregnancy Complications, Infectious/blood , Pregnancy Complications, Infectious/microbiology , Pregnancy Outcome , Rats , Rats, Wistar , Tumor Necrosis Factor-alpha/analysis , Tumor Necrosis Factor-alpha/bloodABSTRACT
Cyclooxygenase-2 (COX-2) expression has been associated with development and progression in spontaneous human and dogs tumors. Studies demonstrated that non-steroidal anti-inflammatory drugs, which inhibit COX enzyme, may be used in the treatment of some tumors. Lymphoma is a systemic disease and the most common hematological malignancy in dogs. There are few studies about COX-2 expression in human and canine lymphoma. In this study, immunohistochemical evaluation for COX-2 expression was performed in 12 dogs with multicentric lymphoma. The diagnosis was confirmed by histopathological examination. Six samples of normal lymph nodes were either used in the study. No COX-2 immunoreactivity was detected in all samples from canine lymphoma and normal lymph nodes, as well previous studies in canine lymphoma(AU)
La expresión de la ciclooxigenasa-2 (COX-2) se ha asociado con el desarrollo y progresión de tumores espontáneos humana y canina. Los estudios han demostrado que los antiinflamatorios no esteroideos, inhibidores de la COX-2 pueden ser utilizados para tratar algunos tumores. El linfoma es una enfermedad sistémica, considerada la neoplasia hematopoyética más frecuente en los perros. Hay pocos estudios sobre la expresión de la COX-2 en los linfomas en los seres humanos y perros. En este estudio, la expresión de COX-2 fue evaluada por inmunohistoquímica en 12 perros con linfoma multicéntrico. El diagnóstico fue confirmado por histopatología. Seis muestras de los ganglios linfáticos normales fueron evaluadas también. En ninguna de las muestras de los ganglios linfáticos normales o neoplásicos se detectó la expresión de la COX-2, corroborando los resultados de estudios previos en el linfoma canino(AU)
Subject(s)
Animals , Male , Female , Dogs , Cyclooxygenase 2 Inhibitors , Immunohistochemistry/methods , Immunohistochemistry , Cyclooxygenase 2 Inhibitors/administration & dosage , Cyclooxygenase 2 Inhibitors/isolation & purification , Cyclooxygenase 2 Inhibitors/therapeutic use , Neoplasms/pathology , Neoplasms/veterinary , Lymphoma/diagnosis , Dog Diseases , Lymphoma/pathology , Lymphoma/veterinary , Dog Diseases/diagnosis , Dog Diseases/pathologyABSTRACT
OBJECTIVE: The neck injury index, NII, developed in ISO 13232 (2005) as a testing and evaluation procedure for assessing the risk of injury to the AO/C1/C2 region of the cervical spine in motorcycle riders is reevaluated using an existing postmortem human subjects (PMHS) data set and resulting in a reformulated NII criterion applicable to PMHS tests. METHODS: A recent series of 36 PMHS head/neck component tests was used to examine the risk of neck injury in frontal impacts and to assess the predictive capability of NII for impacts of various orientations. Using force and moment load cell PMHS experimental data, injury risk was assessed using NII evaluated with the ISO 13232-5 algorithms. RESULTS: The injury risk predictions are compared with the injury outcomes from the head/neck PMHS. The NII criterion underestimated the injury incidence of the PMHS experimental group. The average predicted risk of injuries for the experimental injury tests based on NII across the MAIS levels was 0.7 percent, though there were 11 AIS 3+ injuries observed in the actual testing (30.6%). Using the experimental injury outcomes and the experimental force and moment time histories, the normalizing coefficients from NII are reevaluated to minimize the difference between NII risk assessment and the experimental injury outcome in the least squares (L(2)) basis. This reanalysis is compared with existing human and PMHS neck injury criteria. CONCLUSIONS: By reanalyzing the NII formulation using an existing PMHS injury data set with known forces and moments and known injury outcomes, a new NII(PMHS) is developed that uses PMHS loads to predict injury. This reformulation removes the dependency of the original NII formulation on the forces and moments from motorcyclist anthropomorphic test device (MATD) experiments and simulations yet retains the advantages of the multi-axial neck injury criterion.
Subject(s)
Accidents, Traffic , Cervical Vertebrae/injuries , Motorcycles , Neck Injuries , Risk Assessment/methods , Trauma Severity Indices , Algorithms , Humans , Least-Squares Analysis , Normal Distribution , Survival AnalysisABSTRACT
The aim of this study was to investigate the hematological, hemostatic and biochemical disturbances induced by the injection of Crotalus durissus terrificus venom in dogs under controlled conditions. For this purpose three groups of animals were used: an experimental group (E), which was injected i.m. with C. durissus terrificus venom (1 mg/kg); and two control groups--antivenom (AV) and control (C)--which were injected i.m. with 150 mM NaCl. Groups E and AV were treated i.v. with Crotalus antivenom 2 hours after the first injection. Serum levels of alkaline phosphatase and alanine aminotransferase were increased in groups E and AV at 24 and 48 hours after serumtherapy, respectively. The increased serum levels of myoglobin, creatine kinase and aspartate aminotransferase demonstrated that animals developed rhabdomyolysis. A persistent neutrophilic leukocytosis was already noticeable at 2 hours after envenomation and lasted even after serumtherapy. The animals of groups E and AV presented eosinopenia 24 hours after serumtherapy, and collagen-induced platelet hypoaggregation was observed without thrombocytopenia. Increased levels of fibrinogen/fibrin degradation products (FnDP/FgDP), hypofibrinogenemia, and alpha2-antiplasmin consumption were observed at 2 hours after envenomation, indicating secondary activation of fibrinolysis. Our data suggest that the biochemical and hemostatic disturbances induced by C. durissus terrificus venom in dogs are related to its myotoxic and thrombin-like activities.
Subject(s)
Blood Coagulation Disorders/blood , Crotalid Venoms/toxicity , Crotalus , Snake Bites/blood , Animals , Antivenins/therapeutic use , Aspartate Aminotransferases/blood , Blood Coagulation Disorders/etiology , Blood Coagulation Disorders/therapy , Clinical Chemistry Tests , Creatine Kinase/blood , Dogs , Male , Myoglobin/blood , Rhabdomyolysis/blood , Rhabdomyolysis/etiology , Rhabdomyolysis/therapy , Snake Bites/complications , Snake Bites/therapyABSTRACT
BACKGROUND: Sleep fragmentation can decrease the awake ventilatory control. Since patients with obstructive sleep apnea (OSA) patients exhibit sleep fragmentation linked to respiratory events, their ventilatory control could be impaired. However, most of these patients are also obese, which could conversely increase the ventilatory control. The effect of nasal continuous positive airway pressure (CPAP) on the awake ventilatory control in normocapnic OSA patients is unclear. OBJECTIVES: To study the acute effect of nasal CPAP on the awake ventilatory control in normocapnic OSA patients. METHODS: 12 normocapnic OSA patients, with an apnea/hypopnea index (AHI) >15 with moderate obesity (body mass index: 33.5 kg/m2) and normal pulmonary function tests were submitted to two polysomnography studies (diagnostic and for CPAP titration). Before and after 3 consecutive nights of nasal CPAP we analyzed the hypersomnia score and the ventilatory and the mouth occlusion pressure (P.1) responses at rest (breathing room air and a mixture of 8% CO2 + 40% O2). RESULTS: The respiratory drive of OSA patients as evaluated by P.1 was in the range of the controls of our laboratory. After nasal CPAP, a significant decrease in AHI (mean: 51.9-9.4/h) and arousal (mean: 88.7-43/h) occurred, as well as improvement in nocturnal oxyhemoglobin. There was a marginal increase in DeltaV(E)/DeltaP(ET)CO2 (mean: 1.41-1.87 liters/min/ mm Hg, p = 0.09) and a significant rise in P.1/DeltaP(ET)CO2 (mean: 0.29-0.43 cm H2O/mm Hg), a better indicator of ventilatory drive. CONCLUSIONS: Normocapnic OSA patients increased their awake ventilatory drive response to a hypercapnic and hyperoxic mixture with the use of 3 consecutive nights of nasal CPAP.
Subject(s)
Positive-Pressure Respiration , Respiration , Sleep Apnea, Obstructive/physiopathology , Female , Humans , Hypercapnia/physiopathology , Male , Middle Aged , Respiratory Function TestsABSTRACT
The occurrence of Toxoplasma antibodies in domestic outpatient cats in the city of São Paulo was evaluated using the indirect immunofluorescence assay. A total of 248 blood samples obtained from male and female cats seen at the Veterinary Teaching Hospital at the University of São Paulo between February 1996 and January 1997 were tested. Of these, 17.7% were positive, with a 64 titer being detected in most animals. The frequence of Toxoplasma antibodies was significantly higher in older cats, those fed raw meat and those with free access to the outdoor environment. There was no significant difference in reactivity between males and females. We conclude that diet and free access to the outdoor environment were equally important as predisposing factors to the risk of Toxoplasma infection.
Subject(s)
Antibodies, Protozoan/blood , Cat Diseases/epidemiology , Toxoplasma/immunology , Toxoplasmosis, Animal/epidemiology , Age Distribution , Animals , Antibodies, Protozoan/immunology , Brazil/epidemiology , Cat Diseases/immunology , Cat Diseases/parasitology , Cats , Female , Fluorescent Antibody Technique, Indirect , Male , Sex Distribution , Toxoplasmosis, Animal/immunology , Toxoplasmosis, Animal/parasitologyABSTRACT
UNLABELLED: Beta 2-agonists are considered one of the cornerstones of the asthma therapy, but their short action requires frequent administration and an association with other broncodilators. The development of long-acting beta 2-agonists may represent an important improvement in asthma treatment. PURPOSE: The present study was designed to assess the efficacy and safety of inhaled salmeterol compared to salbutamol in patients with mild-to-moderate asthma. METHODS: After the two run-in weeks, the patients received either salmeterol 50 mg twice a day or salbutamol 200 mg four times a day, over a four week period, following a double blind, parallel group study. Sixty patients had the following inclusion criteria: FEV1 > 50% or PEFR over the past seven days > 50% of predicted normal; reversibility of FEV1 > 15%; symptoms scores > 2 (score 0 and 5) in 4 of the last seven days or PEFR variation > 15%. RESULTS: Seven patients discontinued the protocol (see methods). Of the 53 analyzable patients, 25 were of the salmeterol group and 28 of the salbutamol group. Our results showed that in the run-in period there were not differences among the groups comparing the values of FEV1 in % predicted, morning PEFR and asthma symptoms scores. The improvement rate of morning FEV1 and PEFR in patients who received salmeterol was significantly higher (p < 0.05) compared to the patients who received salbutamol, for two and four weeks of treatment. Also, the salmeterol group have shown reduction of the symptoms in the nocturnal period(significantly in the first fortnight of treatment) demonstrated by the significative increase in the symptoms improvement rate when compared salmeterol and to salbutamol groups. The number of rescue medication inhaled, side effects, heart rate, blood pressure, serum potassium dosage and electrocardiograms, did no show significative differences between the groups. CONCLUSION: This study showed that in mild to moderate asthmatic patients, salmeterol in the dosage of 100 mg/day raised the FEV1 and the morning PEF and led to pronounced decrease in the nocturnal symptoms as compared to salbutamol. The side effects were similar.
Subject(s)
Albuterol/analogs & derivatives , Albuterol/therapeutic use , Asthma/drug therapy , Bronchodilator Agents/therapeutic use , Adult , Female , Humans , Male , Middle Aged , Peak Expiratory Flow Rate , Salmeterol Xinafoate , Spirometry , Statistics, Nonparametric , Time FactorsABSTRACT
Os Beta2-agonistas constituem um dos pilares do tratamento da asma brônquica, porém sua curta duraçao de açao exige uso freqüente e a associaçao com outras drogas broncodilatadoras. O surgimento dos Beta2-agonistas de longa açao pode representar um avanço na terapêutica da asma brônquica. Objetivo. O presente estudo propoe-se a avaliar, em nosso meio, a eficácia e a tolerabilidade do salmeterol (SM), comparativamente ao salbutamol (SB), em pacientes com asma leve e moderada. Métodos. Após uma etapa de estabilizaçao de duas semanas, os pacientes utilizaram salmeterol 50mcg duas vezes ao dia, e salbutamol 200mcg quatro vezes ao dia, durante o período de quatro semanas, seguindo um esquema duplo cego, aleatório, de grupos paralelos. Foram estudados 60 pacientes que preencheram os seguintes critérios de inclusao: VEF1 (Volume Expiratório Forçado no 1 segundo)>50 por cento: variaçao diurna do PFE (Pico do Fluxo Expiratório) > 15 por cento ou resposta do VEF1 ao BD> 15 por cento, gradaçao de sintomas >2 (escala de 0 a 5) em quatro dos últimos sete dias. Resultados. Dos 60 pacientes estudados, sete foram excluídos no período de tratamento (ver Métodos), sendo concluído o estudo com 25 pacientes no grupo salmeterol e 28 no grupo salbutamol. No período de estabilizaçao, nao houve diferença significante entre os grupos, comparando-se os valores de VEF1 em porcentagem do prev., PFE matinal, gradaçao de sintomas e gravidade da asma. O percentual de melhora do VEF1 e do PFE matinal nos pacientes que receberam salmeterol foi significantemente mais elevado entre 2 e 4 semanas de tratamento, em relaçao aos pacientes que receberam salbutamol (p<0,05). Da mesma forma, o grupo salmeterol apresentou reduçao significante nos valores médios dos sintomas no período noturno na 1 quinzena de tratamento. Em relaçao ao número de inalaçao de socorro utilizadas, efeitos colaterais, freqüência cardíaca, pressao arterial sistêmica e dosagem de potássio, nao houve diferença significante entre os grupos. Conclusao. Este estudo demonstrou que, em pacientes com asma leve a moderada, o salmeterol na dose de 100mcg/dia elevou o VEF1, o PFE matinal e apresentou diminuiçao significantemente maior dos sintomas noturnos em relaçao aos observados no grupo salbutamol, e que a tolerância aos medicamentos estudados foi semelhante nos dois grupos.
Subject(s)
Female , Humans , Middle Aged , Adult , Asthma/drug therapy , Bronchodilator Agents/therapeutic use , Adrenergic beta-Agonists/therapeutic use , Albuterol/analogs & derivatives , Albuterol/therapeutic use , Spirometry , Time Factors , Drug Therapy, Computer-Assisted , Bronchodilator Agents , Peak Expiratory Flow Rate , Treatment Outcome , Statistics, Nonparametric , Adrenergic beta-Agonists , Albuterol , Drug ToleranceABSTRACT
In the evaluation of exercise intolerance of patients with respiratory diseases the American Medical Association (AMA) and the American Thoracic Society (ATS) have proposed similar classification for rating aerobic impairment using maximum oxygen uptake (VO2max) normalized for total body weight (ml min-1 kg-1). However, subjects with the same VO2max weight-corrected values may have considerably different losses of aerobic performance (VO2max expressed as % predicted). We have proposed a new, specific method for rating loss of aerobic capacity (VO2max, % predicted) and we have compared the two classifications in a prospective study involving 75 silicotic claimants. Logistic regression analysis showed that the disagreement between rating systems (higher dysfunction by the AMA/ATS classification) was associated with age > 50 years (P < 0.005) and overweight (P = 0.04). Interestingly, clinical (dyspnea score) and spirometric (FEV1) normality were only associated with the VO2max, % predicted, normal values (P < 0.01); therefore, in older and obese subjects the AMA/ATS classification tended to overestimate the aerobic dysfunction. We conclude that in the evaluation of aerobic impairment in patients with respiratory diseases, the loss of aerobic capacity (VO2max, % predicted) should be used instead of the traditional method (remaining aerobic ability, VO2max, in ml min-1 kg-1).
Subject(s)
Disability Evaluation , Exercise Tolerance , Exercise , Oxygen Consumption , Respiratory Tract Diseases/physiopathology , Female , Humans , Inspiratory Capacity , Male , Middle Aged , Prospective Studies , Respiratory Function TestsABSTRACT
In the evaluation of exercise intolerance of patients with respiratory diseases the American Medical Association (AMA) and the American Thoracic Society (ATS) have proposed similar classifications for rating aerobic impairment using maximum oxygen uptake (VO2max) normalized for total body weight (ml min(-1) kg(-1)).However, subjects with the same VO2max weight-corrected values may have considerably different losses of aerobic performance (VO2max expressed as percent predicted). We have proposed a new, specific method for rating loss of aerobic capacity (VO2max, percent predicted) and we have compared the two classifications in a prospective study involving 75 silicotic claimants. Logistic regression analysis showed that the disagreement between rating systems (higher dysfunction by the AMA/ATS classification) was associated with age>50 years (P<0.005) and overweight (P=0.04). Interestingly, clinical (dyspnea score) and spirometric (FEV(1)) normality were only associated with VO2max, percent predicted, normal values (P<0.01); therefore, in older and obese subjects the AMA/ATS classification tended to overestimate the aerobic dysfunction. We conclude that in the evaluation of aerobic impairment in patients with respiratory diseases, the loss of aerobic capacity (VO2max, percent predicted) should be used instead of the traditional method (remaining aerobic ability, VO2max, in ml min(-1) Kg(-1)).
Subject(s)
Humans , Male , Female , Middle Aged , Disability Evaluation , Exercise , Exercise Tolerance , Oxygen Consumption , Respiratory Tract Diseases/physiopathology , Inspiratory Capacity , Prospective Studies , Respiratory Function TestsABSTRACT
Foram avaliadas, pela técnica de imunofluorescência indireta, a freqüência e a magnitude dos títulos de anticorpos antitoxoplasma (Toxoplasma gondii, Nicolle; Manceaux, 1909), em gatos infectados naturalmente pelo vírus da imunodeficiência dos felinos (VIF). Utilizaram-se 115 amostras de soro sangüíneo de gatos negativos ao vírus da leucemia felina que foram divididas em 3 grupos. Os 22 animais do grupo I eram positivos ao VIF. Os 58 animais que compuseram o grupo II eram doentes porém negativos na pesquisa de anticorpos anti-VIF e os 35 felinos do grupo III em hígidos e negativos ao VIF. Os resultados obtidos permitiram concluir que a freqüência de anticorpos antitoxoplasma foi maior no grupo I do que nos grupos II e III. A análise estatística mostrou forte associaçäo entre a infecçäo pelo VIF e a presença de anticorpos antitoxoplasma. Näo se observou diferença entre a magnitude dos títulos de anticorpos antitoxoplasma nos animais positivos e negativos ao VIF. Embora gatos que desenvolvam imunidade raramente eliminem oocistos, näo se sabe exatamente como esta imunidade pode influenciar a eliminaçäo de oocistos naqueles gatos infectados pelo VIF. Em face da alta freqüência de anticorpos antitoxoplasma observada nos animais positivos ao VIF, acredita-se que todos os gatos positivos a esse vírus devam ser avaliados quanto à presença de anticorpos antitoxoplasma
Subject(s)
Animals , Cats , Immunodeficiency Virus, Feline , Toxoplasma , Toxoplasmosis, AnimalABSTRACT
Pregnant rats were subjected to 50% food restriction during the first or the second half of pregnancy, or throughout pregnancy. The effects of intrauterine food restriction, on kidney function and morphometry were studied in newborn and adult (3 months) offspring. No differences in glomerular diameter were observed in newborn restricted rats compared with controls. The number of glomeruli was significantly lower both in newborn and 3-month-old restricted rats. However, glomerular diameter was increased in 3-month-old rats, which suggests that hypertrophic stimuli were present. The medulla/cortex ratio increased in adult rats submitted to food restriction during pregnancy, a finding that agrees with the preserved sodium and acid excretion, and the normal osmolar and free water clearance observed in these groups. These results show that the reduction in glomerular number is still present 3 months after birth in the progeny of mothers submitted to severe food restriction during pregnancy, suggesting impairment of glomerulogenesis even after birth. Intra utero undernutrition can be regarded as an experimental model of glomerular hypertrophy.
Subject(s)
Kidney/pathology , Kidney/physiopathology , Nutrition Disorders/pathology , Nutrition Disorders/physiopathology , Acidosis/etiology , Animals , Body Weight/physiology , Female , Juxtaglomerular Apparatus/pathology , Juxtaglomerular Apparatus/physiopathology , Kidney Function Tests , Kidney Glomerulus/pathology , Kidney Glomerulus/physiopathology , Kidney Tubules/pathology , Kidney Tubules/physiopathology , Male , Nutrition Disorders/metabolism , Organ Size/physiology , Osmolar Concentration , Pregnancy , Pregnancy Complications , Rats , Rats, Wistar , Sodium/urineABSTRACT
Com a finalidade de estudar a magnitude da ocorrência do vírus da leucemia felina (VLF) e do vírus da imunodeficiência dos felinos (VIF) entre os felinos domésticos de Säo Paulo, 401 animais de ambos os sexos, idades e raças variadas, foram submetidos à pesquisa de anticorpos humorais (VIF) e de antígenos virais solúveis (VLF) através do teste imunoenzimático - ELISA (Feline Leukimia Virus Antigen / Feline Immunodeficiency Virus Antibody CITE - Agritech Systems Inc.). Desses, 123 eram felinos sadios e os demais 278 animais eram felinos doentes atendidos no Departamento de Clínica Médica/Hospital Veterinário da FMVZ/USP. Foram observados 8 (6,5 por cento) reagentes ao VIF entre os felinos sadios e 39 (14 por cento) entre os gatos doentes. Em relaçäo ao VLF, 2 (1,6 por cento) dos animais sadios e 30 (10,8 por cento) entre os gatos doentes foram reagentes ao teste imunoenzimático e apenas um animal foi reagente a ambos os vírus. A infecçäo pelo VIF foi mais freqüente entre os machos, quando comparada às fêmeas, na proporçäo de 4:1, näo tendo sido, no entretanto, observada diferença entre machos e fêmeas infectados em relaçäo ao VLF. As infecçöes oportunistas, como a causada por Haemobartonella felis, foram as doenças associadas mais frequentemente observadas tanto nos felinos VLF positivos quanto nos VIF positivos. Em relaçäo aos tumores, a forma mediastinal do linfoma foi a mais freqüente entre os felinos VLF positivos. As demais condiçöes mórbidas que se associaram à infecçäo pelos dois Retrovirus foram de natureza e freqüência variáveis. A idade média dos animais infectados pelo VIF foi de 4,4 mais ou menos 3,0 anos e dos felinos infectados pelo VLF, de 2,4 mais ou menos 1,7 anos. Todos os animais reagentes e sintomáticos näo sobreviveram mais do que dois anos. Por outro lado, näo houve nenhum óbito entre os animais assintomáticos infectados por qualquer um dos Retrovírus durante o mesmo período de observaçäo, demonstrando que o período de pré-patência pós-infecçäo pode ser bastante longo
Subject(s)
Animals , Cats , Feline Acquired Immunodeficiency Syndrome/diagnosisABSTRACT
OBJECTIVE: The purpose of this study was to assess the relationships between selected nutritional factors and blood lead levels of preschool children. METHODOLOGY: Data on 296 children, aged 9 to 72 months, who were cared for at the University of Maryland at Baltimore Pediatric Ambulatory Center were examined in this cross-sectional study. Nutritional status, socioeconomic aspects, medical history, and potential sources of lead exposure were assessed. Blood samples were evaluated for levels of blood lead, serum iron (ferritin), free erythrocyte photoporphyrin, calcium, and hematocrit. RESULTS: The average blood lead level was 11.4 micrograms/dL. Multicollinearity of nutritional factors was addressed using regression techniques. After adjusting for confounders, significant positive associations with blood lead were found for total caloric intake (P = .01) and dietary fat (P = .05). CONCLUSIONS: The findings of this study suggest that even when behavioral and environmental exposures to lead were statistically controlled, total caloric intake and dietary fat each had an independent and significant association with the level of blood lead.